About NeuWave Medical
NeuWave Medical develops tools that deliver energy to the human body to treat a range of medical conditions. NeuWave is a spin-off company from the University of Wisconsin - Madison. NeuWave arose as the result of an academic collaboration between engineers and physicians who wished to improve the ability to treat cancer and other clinical problems.
Missing: NeuWave Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: NeuWave Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing NeuWave Medical
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned NeuWave Medical in 1 CB Insights research brief, most recently on Sep 10, 2020.
Expert Collections containing NeuWave Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
NeuWave Medical is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
NeuWave Medical Patents
NeuWave Medical has filed 1 patent.
Cardiac arrhythmia, Cardiac electrophysiology, Surgical removal procedures, Medical equipment, Antiarrhythmic agents
Cardiac arrhythmia, Cardiac electrophysiology, Surgical removal procedures, Medical equipment, Antiarrhythmic agents
Latest NeuWave Medical News
Nov 29, 2022
News provided by Share this article Share this article This report provides strategists, marketers and senior management with the critical information they need to assess the global tumor ablation therapy devices market. The global tumor ablation therapy devices market is expected to grow from $0.49 billion in 2021 to $0.56 billion in 2022 at a compound annual growth rate (CAGR) of 14.1%. The market is expected to grow to $0.97 billion in 2026 at a compound annual growth rate (CAGR) of 15%. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates Create regional and country strategies on the basis of local data and analysis Identify growth segments for investment Outperform competitors using forecast data and the drivers and trends shaping the market Understand customers based on the latest market research findings Benchmark performance against key competitors Utilize the relationships between key data sets for superior strategizing Suitable for supporting your internal and external presentations with reliable high quality data and analysis Major players in the tumor ablation therapy devices market are Galil Medical Inc, Misonix Inc, HealthTronics, Angiodynamics, Boston Scientific Corporation, Medtronic Plc, EDAP TMS S.A, Neuwave Medical Inc, BVM Medical Limited, and Erbe Elektromedizin GmbH. The tumor ablation therapy devices market consists of sales of tumor ablation devices and related services that are used in hospitals and oncology clinics. Tumor ablation is the technique used to extract the tumors using a needle, to insert them in the tumor organ using imaging techniques. The main technologies in the tumor ablation therapy devices are radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others. Irreversible electroporation (IRE) in tumor ablation therapy is a new tissue ablation method in which micro to millisecond electrical pulses are supplied to undesirable tissue to produce cell necrosis by irreversible cell membrane permeabilization. The treatments included are surgical, laparoscopic, and percutaneous that are used in various applications such as kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. The various end-users of tumor ablation therapy devices are hospitals, oncology clinics, and others. North America was the largest region in the tumor ablation therapy devices market in 2021. Asia Pacific was the second largest region in the tumor ablation therapy devices market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The increasing prevalence of cancer is a key factor driving the growth of the tumor ablation therapy devices market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. Tumor ablation is a minimally invasive procedure widely used in the treatment of lung, liver, kidney, and bone tumors. Product recalls of tumor ablation devices due to technical issues are expected to hinder the growth of the tumor ablation therapy devices market. The companies are retrieving their products from the market due to safety concerns. For instance, Covidien Emprint Long Percutaneous Antenna with Thermosphere Technology, a tumor ablation device from Medtronic had recalled its devices due to the disengagement of ceramic trocar tip of the Emprint ablation from the needle shaft post-ablation. Similarly, in June 2018, Accurian RF Ablation by Medtronic Sofamor Danek USA Inc was recalled due to the difficulty in insertion. The product recalls caused a financial burden on the companies hindering the tumor ablation therapy devices market. Major companies operating in the tumor ablation therapy devices are focusing on technology advancements for shorter procedures, increased safety, lower exposure to radiation, faster learning curves, and improved outcomes J&J medicals have released a microwave ablation system called NEUWAVE, which is the first minimally invasive device to put electrodes into cancer cells and thereby increase the temperature around them for burning the cancer cells. The countries covered in the tumor ablation therapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. Key Topics Covered:
NeuWave Medical Frequently Asked Questions (FAQ)
When was NeuWave Medical founded?
NeuWave Medical was founded in 2004.
Where is NeuWave Medical's headquarters?
NeuWave Medical's headquarters is located at 3529 Anderson Street, Madison.
What is NeuWave Medical's latest funding round?
NeuWave Medical's latest funding round is Acquired.
How much did NeuWave Medical raise?
NeuWave Medical raised a total of $59.74M.
Who are the investors of NeuWave Medical?
Investors of NeuWave Medical include Ethicon, Venture Investors, H.I.G. BioHealth Partners, Versant Ventures, Venture Management and 7 more.
Who are NeuWave Medical's competitors?
Competitors of NeuWave Medical include Veran Medical Technologies, Aeris Therapeutics, Sanarus, Ablation Frontiers, Kjaya and 12 more.
Compare NeuWave Medical to Competitors
Abla-Tx Inc is a private company founded in 2005 to develop a software based algorithm to monitor thermal ablation of tumors. Abla-Tx has been formed to help guide minimally invasive methods for the treatment of all malignant and benign solid tumors. A patented method of monitoring temperature during thermal ablation in conjunction with CT and digital x-ray imaging will be developed and commercialized. Regulatory approval will be sought to allow the sale of a software based thermal mapping system that will be used in conjunction with CT and planar x-ray imaging systems.
Arbel-medical develops minimally invasive Cryo-therapy products, for the treatment of breast tumors and other internal diseased tissue.
RadioTherapeutics Corporation is developing tools for minimally invasive treatment of solid tumors. The RF 2000B is used by surgeons, interventional radiologists, and gastroenterologists to predictably, precisely and homogeneously ablate diseased or unwanted volumes of soft tissues.
Monteris Medical develops MRI-guided neurosurgical ablation tools and solutions for neurosurgeons. The company creates a system enabling surgeons to reach lesions that are difficult to access with standard surgery or were previously considered inoperable. Monteris offers 'The NeuroBlate System', a neurosurgical ablation device providing controlled therapy for brain lesions, the Monteris Mini-Bolt, a cranial bolt system that enables a robotic interface for protected and precise therapy delivery, as well as the AtamA Stabilization System for MRI-guided neurosurgical procedures requiring head fixation. It serves clients in the healthcare sector. The company was founded in 1999 and is based in Hopkins, Minnesota.
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.